CompletedNCT00593099
Bupropion or placebo for smoking cessation in bipolarity
About this title
Read the official source — NCT00593099Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- New HavenSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateApril 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 5
- Sponsor
- National Institute on Drug Abuse (NIDA)
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00593099
- Official title
Show the full official title
A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Affective Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New Haven
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is National Institute on Drug Abuse (NIDA), a research institute.
Did this study involve medication?
Yes. The study involved medication, including Bupropion and Placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
